Jeena Sikho Lifecare Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Mar 2022 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 75 Cr | 174 Cr | 190 Cr | 222 Cr | 216 Cr |
| Operating expenses (approx.) | 66 Cr | 94 Cr | 96 Cr | 118 Cr | 134 Cr |
| EBITDA | 9 Cr | 80 Cr | 93 Cr | 103 Cr | 81 Cr |
| OPM % | 12.3% | 45.8% | 49.2% | 46.6% | 37.7% |
| Other income | 0.28 Cr | 1 Cr | 1 Cr | 3 Cr | 3 Cr |
| Interest | 0.51 Cr | 2 Cr | 4 Cr | 3 Cr | 4 Cr |
| Depreciation | 2 Cr | 10 Cr | 10 Cr | 11 Cr | 16 Cr |
| Profit before tax | 7 Cr | 69 Cr | 79 Cr | 89 Cr | 61 Cr |
| Tax % | 25.9% | 25.2% | 25.4% | 25.1% | 26.4% |
| Net profit | 5 Cr | 51 Cr | 59 Cr | 67 Cr | 45 Cr |
| EPS (₹) | ₹4.96 | ₹4.13 | ₹4.73 | ₹5.36 | ₹3.63 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2022 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
| Sales | 147 Cr | 469 Cr | 801 Cr | Sign in for TTM |
| Operating expenses (approx.) | 127 Cr | 338 Cr | 443 Cr | Sign in for TTM |
| EBITDA | 20 Cr | 131 Cr | 358 Cr | Sign in for TTM |
| OPM % | 13.3% | 28.0% | 44.7% | Sign in for TTM |
| Other income | 1 Cr | 6 Cr | 8 Cr | Sign in for TTM |
| Interest | 1 Cr | 0.51 Cr | 13 Cr | Sign in for TTM |
| Depreciation | 3 Cr | 9 Cr | 48 Cr | Sign in for TTM |
| Profit before tax | 15 Cr | 122 Cr | 297 Cr | Sign in for TTM |
| Tax % | 25.8% | 25.7% | 25.5% | Sign in for TTM |
| Net profit | 11 Cr | 91 Cr | 222 Cr | Sign in for TTM |
| EPS (₹) | ₹11.11 | ₹36.50 | ₹17.84 | Sign in for TTM |
| Dividend payout % | 0.0% | 11.4% | 6.2% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2022 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity capital | 10 Cr | 25 Cr | 25 Cr |
| Reserves | 26 Cr | 248 Cr | 442 Cr |
| Borrowings | 7 Cr | — | 0.19 Cr |
| Other liabilities | 18 Cr | 55 Cr | 207 Cr |
| Total liabilities | 62 Cr | 328 Cr | 674 Cr |
| Fixed assets (net) | 28 Cr | 92 Cr | 118 Cr |
| CWIP | 5 Cr | — | 2 Cr |
| Investments | 0.0000 Cr | 4 Cr | 110 Cr |
| Other assets | 24 Cr | 152 Cr | 341 Cr |
| Total assets | 62 Cr | 328 Cr | 674 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2022 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from operating activity | 16 Cr | 69 Cr | 254 Cr |
| Cash from investing | -18 Cr | -70 Cr | -202 Cr |
| Cash from financing | -5 Cr | -0.69 Cr | -59 Cr |
| Net cash flow | -6 Cr | -2 Cr | -7 Cr |
| Free cash flow (OCF − Capex) | -0.73 Cr | 27 Cr | 220 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2022 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| ROCE % | 37.7% | 44.9% | 66.4% |
| ROE % | 30.8% | 33.2% | 47.5% |
| Debtor days | — | 76 | — |
| Inventory days | 16 | 9 | 9 |
| Days payable | — | 7 | — |
| Cash conversion cycle | 16 | 77 | 9 |
| Debt / equity | 0.18 | — | 0.0004 |
| Current ratio | 0.90 | 2.91 | 3.25 |
| Net debt / EBITDA | 0.21 | -0.20 | -0.05 |
Compare with peers
Loading peers…